FBXO22 and acute myeloid leukemia: Thus, FBXO22 appears to be uniquely hijacked to play an essential role in MLLr AML pathogenesis and LSC maintenance, as it is dispensable for normal hematopoiesis, suggesting that FBXO22 is a feasible target for AML therapy.